Dapagliflozin improves left ventricular diastolic function and reduces inflammatory cytokines in heart failure with preserved ejection fraction
A common diabetes drug added to heart failure treatment reduces inflammation and improves heart function in a patient group with historically few medication options.
This retrospective cohort study demonstrates that dapagliflozin added to standard therapy improves left ventricular diastolic function and significantly reduces pro-inflammatory cytokines (IL-6, TNF-alpha, hs-CRP) and NT-proBNP in HFpEF patients over six months. The findings provide mechanistic and clinical evidence supporting SGLT2 inhibitor use in HFpEF, a disease with historically limited pharmacological options.
What the study was
- Study design
- Retrospective cohort study
- Category
- T7: Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
- Maturity
- Validated
- Journal
- American Journal of Translational Research
Why it surfaced
HFpEF is a growing epidemic with few proven therapies; this study provides actionable evidence on dapagliflozin anti-inflammatory and diastolic improvement effects supporting near-term clinical implementation aligned with the SGLT2 watchlist focus.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.